Objective: To evaluate the pharmacokinetics and bioequivalence of syingopicroside self-sustained-release tablets in rabbits. Method: The blood concent ration of syingopicroside of 6 rabbits was determined by HPLC and the pharmacokinetic parameters were calculated with statistical moment and confidence interval after administered random crossover with single dose of self-sustained-release syingopicroside tablets (test pharmaceutics

T) or the self-common tablets (reference pharmaceutics

R). Result: The relative bioavailability of self-sustained-release syingopicroside tablets was 132.6%. In comparison with self-common tablets

the Tmax extended significantly and the peak was prolonged gentle; the 90% confidence interval of AUC0-t was 115.25%-144.44%; the 90% confidence interval of Cmax was 51.33%-78.53%. Conclusion: A good slow-release effect was found when compared test formulation with the reference reagent.